Products for Research Use Only

PFK-015

CAT: 0804-HY-12204-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12204-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PFK-015, a derivative of 3PO, is a specific PFKFB3 inhibitor. PFK-015 inhibits recombinant PFKFB3 with an IC50 value of 110 nM and inhibits PFKFB3 activity in cancer cells with an IC50 value of 20 nM. PFK-015 can be used for the research of multiple cancers such as lung cancer, stomach cancer, colon cancer and esophageal squamous cell carcinoma (ESCC) [1][2].
CAS Number
4382-63-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy
Type
Reference compound
Related Pathways
Autophagy
Applications
Cancer-programmed cell death
Field of Research
Cancer; Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/PFK-015.html
Purity
99.80
Solubility
DMSO : 25.2 mg/mL (ultrasonic; warming)
Smiles
O=C(C1=CC=NC=C1)/C=C/C2=NC3=CC=CC=C3C=C2
Molecular Formula
C17H12N2O
Molecular Weight
260.29
Precautions
H302, H315, H319, H335
References & Citations
[1]Jia Bo Zheng, et al. Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer. Oncoimmunology. 2022 May 25;11 (1) :2079182. |[2]Brian Clem, et al. Characterization of a novel small molecule antagonist of 6-phosphofructo-2-kinase that suppresses glucose metabolism and tumor growth. ORAL PRESENTATIONS - PROFFERED ABSTRACTS| APRIL 15 2011.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported